Arbutus (ABUS) Trade Idea - LNP Litigation and Imdusiran Data Create a High-Reward Set-Up
Arbutus is a small-cap clinical-stage biotech where two near-term vectors - LNP-related litigation and follow-up imdusiran efficacy readouts - can produce outsized moves. Market capitalization sits near $844M while recent clinical data showed meaningful reductions in HBsAg. High short interest and above-average volume amplify both upside and downsi…